Stefin A Scaffold Protein Peptide Display Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current scaffold proteins for displaying peptides, such as peptide aptamers, face challenges including instability, interference with cellular processes, and limited ability to present peptides effectively due to structural deformation and post-translational modifications, particularly with existing proteins like thioredoxin A.
Innovation Solution
Development of Stefin A-based scaffold proteins, specifically the Stefin A Triple Mutant (STM) with mutations at the Leu 73, V48D, and G4W sites, which are biologically neutral, stable, and capable of presenting peptides without structural deformation, allowing for increased avidity and specificity in peptide binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If thioredoxin A is used as a scaffold protein, then peptide display capability is provided, but biological interference occurs and stability is reduced
Solution Approach 1:
The invention extracts only the structural framework of stefin A while removing its biological activity through mutations. The scaffold retains the ability to display peptides but loses its original protease inhibition function, achieving biological neutrality while maintaining structural integrity for peptide presentation.
Solution Approach 2:
The invention changes the biological parameters of stefin A by introducing specific mutations (V48D, G4W, L73P) that alter its functional properties. These parameter changes eliminate biological interference while preserving the structural framework needed for stable peptide display, transforming an active protein into a neutral scaffold.
2Area of stationary object
If larger scaffold proteins like antibodies are used, then peptide presentation surface is increased, but manipulation difficulty and structural instability increase
Solution Approach 1:
The invention creates a simplified copy of the scaffold function using a small, compact stefin A-based structure. Instead of using large antibody frameworks, it replicates the essential peptide display capability in a minimized form that is easier to manipulate and more structurally stable, achieving the same functional goal with reduced complexity.
3Object-generated harmful factors
If stefin A is mutated to achieve biological neutrality, then cellular interference is reduced, but structural deformation may occur
Solution Approach 1:
The invention applies local quality changes by introducing mutations at specific positions (V48D, G4W, L73P) rather than throughout the entire structure. These localized mutations eliminate biological activity at specific sites while preserving the overall structural framework, achieving biological neutrality without compromising global structural integrity.
Data Source
AI summary
The present invention relates to the use of Stefin A as a scaffold protein for the display of inserted peptides, particularly wherein the Stefin A is a human Stefin A. Several mutations are advantageously made in the wild type stefin A sequence to improve it as a scaffold; preferably the Stefin A comprises a heterologous peptide insertion at the Leu 73 site. Furthermore, preferably the scaffold protein comprises a V48D mutation; preferably the scaffold protein comprises a G4W mutation. Preferably the scaffold comprises Leu73, V48D and G4W mutations. The invention also relates to the scaffold proteins themselves, in particular a stefin A polypeptide having the Leu73, V48D and G4W mutations, such as shown as SEQ ID NO: 1. The invention also relates to a method for identifying binding proteins and to peptide A (RLNKPLPSLPV) and its use in treating yeast infections.